Coeptis Therapeutics

Focus: Coeptis Therapeutics is a cell therapy platform company focused on oncology and gene therapy applications, operating as a pre-revenue biotech from its Pennsylvania headquarters.

Oncology Gene Therapy Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Coeptis Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Coeptis Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

DVX201

COVID-19 Pneumonia

Phase 1

Clinical Trials (1)

NCT04900454Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19

Phase 1

Help build intelligence for Coeptis Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in cell therapy, a high-growth modality with significant clinical validation in oncology
Focused pipeline allows deep specialization in emerging cell and gene therapy platforms rather than broad portfolio management
Early-stage position offers equity upside potential and the chance to build capabilities from inception

Watch Out For

Zero active job openings signal either early hiring stage, limited headcount, or potential operational constraints
Pre-revenue status with unknown funding creates cash runway uncertainty and restructuring risk typical of pre-clinical biotech
Minimal public scientific output (0 publications) raises questions about research productivity and intellectual property strength

Generated by Claude from Coeptis Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

DVX201

AML, Adult Recurrent

Phase 1

Clinical Trials (1)

NCT04901416Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS

Phase 1

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Infectious Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

1 pipeline

Marketed

Pipeline